The characteristics of benign prostatic hyperplasia (BPH) in Rumah Sakit Umum Haji Medan
Shahrul, R.
Journal of Public Health and Epidemiology 10(1): 16-20
2018
ISSN/ISBN: 2141-2316 Document Number: 467837
Document emailed within 1 workday
Related Documents
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111Isaacs, J.T. 1984: Common characteristics of human and canine benign prostatic hyperplasia Progress in Clinical and Biological Research 145: 217-234
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Kletscher, B.A.; Oesterling, J.E. 1995: Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 423-430
Gu, F. 2000: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China Chinese Medical Journal 113(4): 299-302
Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Abdul-Muhsin, H.M.; Jakob, N.J.; McLemore, R.M.; McAdams, S.B.; Humphreys, M.R. 2016: Infectious complications associated with the use of temporary prostatic urethral stents in patients with benign prostatic hyperplasia Canadian Journal of Urology 23(5): 8465-8470
Pretlow, T.G.; Whitehurst, G.B.; Pretlow, T.P.; Hunt, R.S.; Jacobs, J.M.; McKenzie, D.R.; McDaniel, H.G.; Hall, L.M.; Bradley, E.L. 1982: Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia Cancer Research 42(11): 4842-4848
Blanc, M.; Sacrini, A.; Avogadro, A.; Gattamorta, M.; Lazzerini, F.; Gattoni, F.; Cretti, F. 1998: Prostatic volume: suprapubic versus transrectal ultrasonography in the control of benign prostatic hyperplasia La Radiologia Medica 95(3): 182-187
Maygarden, S.J.; Strom, S.; Ware, J.L. 1992: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia Archives of Pathology and Laboratory Medicine 116(3): 269-273
Schönberger, B. 1986: Benign prostatic hyperplasia Zentralblatt für Chirurgie 111(10): 569-588
Hiraoka, Y.; Sa, I. 2002: Biochemical diagnosis of benign prostatic hyperplasia (including differential diagnosis with prostatic carcinoma) Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 11): 342-345
Tan, E.C. 1995: Pharmacotherapy in benign prostatic hyperplasia Annals of the Academy of Medicine Singapore 24(4): 615-618
Neal, D.E.; Hegarty, P. 2003: Key questions in benign prostatic hyperplasia Practitioner 247(1652): 886-889
Rodríguez, J.V. 2001: Prostatotomy in benign prostatic hyperplasia. Why? Archivos Espanoles de Urologia 54(7): 667-673
Thomas, D. 1997: When to investigate benign prostatic hyperplasia Practitioner 241(1576): 408-413
Concato, J.; Horwitz, R.I.; Feinstein, A.R.; Elmore, J.G.; Schiff, S.F. 1993: Therapies for benign prostatic hyperplasia JAMA 269(7): 867
Garnett, S.; Abrams, P. 2001: Managing benign prostatic hyperplasia Practitioner 245(1627): 830
Ekman, P.; Andersen, J.T.; Wolf, H. 1996: Finasteride in the treatment of benign prostatic hyperplasia Acta Urologica Belgica 64(1): IX-XII